According to The Insight Partners' research, the North America Lab Automation Market was valued at US$ 3,002.8 Million in 2024 and is expected to reach US$ 4,416.1 Million by 2031, registering a CAGR of 5.9% from 2025 to 2031.
AI-Driven automation and Standardization & Interoperability (SiLA) are among the critical factors attributed to drive the North America lab automation market growth.
Integrating AI into fully autonomous diagnostic systems aims to eliminate the last vestiges of manual intervention in clinical workflows. On July 24, 2025, Scopio Labs announced the unveiling of its Complete Blood Morphology (CBM) analyzer-the first-of-its-kind AI-powered solution designed to automate blood morphology analysis fully. Traditionally, one of the most complex and manually intensive processes in diagnostic hematology, blood cell morphology has long resisted automation due to the nuanced interpretation required. With the CBM platform, Scopio Labs introduces a paradigm shift by combining Full-Field Cell Morphology imaging with advanced AI algorithms to deliver autonomous, standardized morphology analysis and reporting at scale. This development aligns with the future of lab automation, where the market is moving beyond mechanization and toward intelligent, decision-capable systems that process samples and interpret complex data. The CBM analyzer reflects a broader trend of automating sophisticated diagnostic processes that previously depended heavily on skilled human expertise. The technology promises to increase efficiency, reproducibility, and diagnostic throughput, while reducing reliance on scarce specialist labor. Such solutions are vital as healthcare systems worldwide grapple with growing patient volumes, workforce shortages, and mounting pressure to deliver faster, more accurate diagnostic insights.
Scopio's achievement underscores the commercial and investment appeal of next-generation lab automation. The company's Series D funding round expansion to US$ 52 million, supported by Viola Growth's US$ 10 million investment, highlights the strong market confidence in platforms that fuse automation, AI, and digital imaging to transform diagnostics. This funding is expected to accelerate the go-to-market strategy for CBM, positioning Scopio at the forefront of AI-enabled laboratory innovation. In the broader context of lab automation trends, the rise of autonomous systems such as Scopio's CBM signals a shift from incremental improvements to full-stack automation, where machines perform technical tasks and cognitive functions. As laboratories evolve into AI-enhanced diagnostic environments, the ability to combine high-resolution imaging, real-time analysis, and standardized reporting within a single automated workflow will become a defining feature of the future lab. The CBM platform represents more than a product innovation; it exemplifies a new era in lab automation, where AI assists scientists and drives the diagnostic process.
On the contrary, the high capital and maintenance costs hamper the growth of the North America lab automation market.
North America Lab Automation Market Segmentation Analysis:
- By Type, the North America Lab Automation Market is segmented into Equipment and Software. The Equipment segment is projected to expand at 5.7% CAGR during 2025 - 2031.
- By Equipments, the North America Lab Automation Market is segmented into Automated Workstations, Liquid Handling Systems, Robotic Systems, Microplate Readers, Automated Storage and Retrieval Systems (ASRS), and Others. The Automated Workstations segment is projected to expand at 6.5% CAGR during 2025 - 2031.
- By Application, the North America Lab Automation Market is segmented into Clinical Diagnostics, Drug Discovery, Proteomics Solutions, Genomics Solutions, and Others. The Clinical Diagnostics segment is projected to expand at 6.0% CAGR during 2025 - 2031.
- By End User, the North America Lab Automation Market is segmented into Hospitals and Diagnostic Centers, Pharmaceutical Companies, Contract Research Organizations (CROs), and Educational and Research Institutions. The Hospitals and Diagnostic Centers segment is projected to expand at 6.2% CAGR during 2025 - 2031.
By country, the North America Lab Automation Market is categorized into the United States, Canada, and Mexico. The United States is projected to expand at 6.0% CAGR during 2025 - 2031.
Key players operating in the Lab Automation Market are Honeywell International Inc., Siemens AG, Abbott Laboratories, bioMerieux SA, Eppendorf SE, Revvity Inc., Agilent Technologies Inc., and Analytik Jena GmbH+Co. KG, Danaher Corp, and Thermo Fisher Scientific Inc., among others.
- In October 2024, Thermo Fisher Scientific Inc. launched the Thermo Scientific iCAP MX Series ICP-MS to simplify trace element analysis with inductively coupled plasma mass spectrometry (ICP-MS). The launch includes a new single quadrupole Thermo Scientific iCAP MSX ICP-MS and triple quadrupole Thermo Scientific iCAP MTX ICP-MS designed for environmental, food, industrial and research labs to analyze routine and challenging trace elements to detect and mitigate harmful substances.
- In April 2025, Siemens AG announces that it has signed an agreement to acquire Dotmatics, a leading provider of Life Sciences R&D software based in Boston, for $5.1 billion from Insight Partners. This acquisition represents a strategic milestone for Siemens, expanding its comprehensive Digital Twin technology and AI-powered software into this rapidly growing complementary market. The US company offers a market-leading platform with a highly profitable portfolio of scientific applications and multi-modal data management for Life Sciences R&D. The company's offering accelerates customers' innovation, delivering next-generation collaboration and contextualized data to enable AI-powered multi-modal drug development.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com